These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 6765278)

  • 1. [Nadolol, a long-term acting beta blocking agent, in the treatment of essential arterial hypertension].
    Semplicini A; Pessina AC; Rossi GP; Tagliafierro R; Lusiani L; Castellani V; Bedogni F; Mazzucato A; Ronsisvalle G
    Cardiologia; 1982 Sep; 27(9):853-64. PubMed ID: 6765278
    [No Abstract]   [Full Text] [Related]  

  • 2. [Nadolol, a long-acting beta-blocker, in the treatment of essential arterial hypertension].
    Semplicini A; Pessina AC; Rossi GP; Tagliafierro R; Lusiani L; Castellani V; Bedogni F; Mazzucato A; Ronsisvalle G
    Cardiologia; 1982 Sep; 27(9):853-64. PubMed ID: 6765448
    [No Abstract]   [Full Text] [Related]  

  • 3. A long-term evaluation of nadolol, a long-acting beta-adrenergic blocking agent, in the management of hypertension in general practice.
    O'Callaghan EG
    Br J Clin Pract; 1982 Jun; 36(6):235-9. PubMed ID: 6128994
    [No Abstract]   [Full Text] [Related]  

  • 4. [Short-term effects of a treatment with methoprolol (a selective beta 1-blocking agent) in essential hypertension. Changes of haemodynamics, renin, aldosterone, sodium and potassium balance (author's transl)].
    Novarini A; Bruschi G; Aurier E; Biggi A; Coruzzi P; Curti M; Rolli A; Borghetti A
    G Ital Cardiol; 1979; 9(11):1259-67. PubMed ID: 399932
    [No Abstract]   [Full Text] [Related]  

  • 5. [Evaluation of the antihypertensive effect and tolerability of nadolol administered alone or in association with bendroflumethiazide].
    Gragnoli G; Righi GA; Turchetti V; Mondillo S; Kristodhullu A
    Minerva Med; 1984 Nov; 75(43):2609-15. PubMed ID: 6392936
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Beta-blockers and arterial hypertension: comparison between nadolol and propranolol].
    Abate G; Polimeni RM; Di Peppe MC; Guarino F; Troja C; Marisi F; Cerritelli E; Brillante C; De Angelis M
    Clin Ter; 1982 Aug; 102(3):283-291. PubMed ID: 7140182
    [No Abstract]   [Full Text] [Related]  

  • 7. Beta-blockers and the kidney.
    Epstein M; Oster JR
    Miner Electrolyte Metab; 1982 Nov; 8(5):237-54. PubMed ID: 6132329
    [No Abstract]   [Full Text] [Related]  

  • 8. [Treatment of essential arterial hypertension with nadolol and bendroflumethiazide].
    Marchetta F; Chiarini C; Degli Esposti E; Santoro A; Sturani A; Zuccalà A; Zucchelli P
    Clin Ter; 1983 Aug; 106(3):209-12. PubMed ID: 6627892
    [No Abstract]   [Full Text] [Related]  

  • 9. Preserved renal perfusion during treatment of essential hypertension with the beta blocker nadolol.
    O'Connor DT; Barg AP; Duchin KL
    J Clin Pharmacol; 1982 Apr; 22(4):187-95. PubMed ID: 6124557
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term renal hemodynamic effects of nadolol in patients with essential hypertension.
    Frohlich ED; Messerli FH; Deslinski GR; Kobrin I
    Am Heart J; 1984 Oct; 108(4 Pt 2):1141-3. PubMed ID: 6148875
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Atenolol, a new beta-adrenergic blocking agent, in treatment of hypertension: therapeutic effect and hemodynamic changes (author's transl)].
    Shen JQ
    Zhonghua Xin Xue Guan Bing Za Zhi; 1981 Jun; 9(2):94-8. PubMed ID: 7032869
    [No Abstract]   [Full Text] [Related]  

  • 12. Isometric exercise before and after nadolol treatment in uncomplicated essential hypertension.
    Corea L; Bentivoglio M; Provvidenza M
    Int J Clin Pharmacol Res; 1984; 4(1):35-40. PubMed ID: 6469432
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Ambulatory treatment of hypertension with the beta-blockader corgard (nadolol)].
    Charyev KhE; Erina EV; Iurenev AP; Lediasheva GA
    Ter Arkh; 1984; 56(11):43-6. PubMed ID: 6523386
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nadolol in essential hypertension: effect on ambulatory blood pressure, renal haemodynamics and cardiac function.
    Dupont AG; Vanderniepen P; Bossuyt AM; Jonckheer MH; Six RO
    Br J Clin Pharmacol; 1985 Aug; 20(2):93-9. PubMed ID: 2864051
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prorenin and beta-blockade in hypertension.
    McKenna F; Davison AM
    Proc Eur Dial Transplant Assoc; 1983; 20():566-71. PubMed ID: 6140678
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Efficacy of the nadolol-bendroflumethiazide combination in the treatment of arterial hypertension].
    Zecchi P; Bellocci F; Santarelli P; Iannarelli M
    Clin Ter; 1986 Jan; 116(1):19-24. PubMed ID: 2870837
    [No Abstract]   [Full Text] [Related]  

  • 17. Nadolol, a once daily treatment for hypertension: multi-centre clinical evaluation.
    Jackson DA
    Br J Clin Pract; 1980 Jul; 34(7):211-21. PubMed ID: 6107120
    [No Abstract]   [Full Text] [Related]  

  • 18. Acute effects of tertatolol and nadolol on systemic and renal hemodynamics in patients with essential hypertension.
    Degaute JP; Naeije R; Abramowicz M; Leeman M; Schoutens A; Prost JF
    Am J Hypertens; 1988 Jul; 1(3 Pt 3):263S-268S. PubMed ID: 3415803
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Short term treatment of essential arterial hypertension with atenolol: effect on the renin-angiotensin-aldosterone system and on hemodynamic parameters].
    Indovina I; Salerno L; Licata G; Pepe S; Custro N
    Clin Ter; 1983 Feb; 104(3):223-6. PubMed ID: 6861459
    [No Abstract]   [Full Text] [Related]  

  • 20. [Adrenergic beta receptor blockader celiprolol in the treatment of patients with arterial hypertension].
    Kapitanenko AM; Dulin PA
    Klin Med (Mosk); 1990 Feb; 68(2):65-9. PubMed ID: 2139911
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.